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Importance: S100A12 is a calcium binding protein which is involved in inflammation and
progression of atherosclerosis.
Objective: We sought to investigate the utility of S100A12 as a biomarker for the
early diagnosis and prognostication of patients presenting with ST-segment elevation
myocardial infarction (STEMI).
Design, Setting, and Participants: S100A12 was measured in 1023 patients
presenting to the emergency department with acute chest pain between June 2012 and
November 2015. An independent cohort of 398 patients enrolled at 3 different hospitals
served as a validation cohort.
Main Outcomes and Measures: The primary clinical endpoint of interest was major
adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death,
MI, stroke, or hospitalization for heart failure.
Results: A total of 438/1023 patients (42.8%) in the diagnosis cohort were adjudicated
as STEMI, among whom plasma S100A12 levels increased within 30 min and peaked
1–2 h after symptom onset. Compared with high-sensitivity cardiac troponin T and
creatine kinase-MB isoenzyme, S100A12 more accurately identified STEMI, especially
within the first 2 h after symptom onset (area under the curve 0.963 compared with
0.860 for hscTnT and 0.711 for CK-MB, both P < 0.05). These results were consistent
in the 243-patient validation cohort. The 1-year rate of MACCE was greatest in patients
in the highest peak S100A12 tertile, intermediate in the middle tertile and least in
the lowest tertile (9.3 vs. 5.7 vs. 3.0% respectively, Ptrend = 0.0006). By multivariable
analysis the peak plasma concentration of S100A12 was an independent predictor
of MACCE within 1 year after STEMI (HR, 1.001, 95%CI, 1.000–1.002; P = 0.0104).
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Conclusions and Relevance: S100A12 rapidly identified patients with STEMI, more
accurately than other cardiac biomarkers, especially within the first 2 h after symptom
onset. The peak plasma S100A12 level was a strong predictor of 1-year prognosis
after STEMI.
Keywords: S100A12, ST-segment elevation myocardial infarction, diagnosis, prognosis, cardiovascular disease(s)

KEY POINTS

a relationship between S100A12 and atherothrombotic events
(7). S100A12 predominantly localizes in activated macrophages
in atherosclerotic plaques. Circulating S100A12 levels are not
elevated in patients with stable coronary artery disease but are
increased in those with acute coronary syndromes (ACS) and
after percutaneous coronary intervention (PCI) due to acute
release of S100A12 from macrophages after plaque rupture
or mechanical injury (8, 9). We hypothesize that the plasma
concentration of S100A12 might be elevated in the early stage
of STEMI due to plaque rupture or erosion, and thus serve
as an effective biomarker for the early diagnosis of STEMI in
patients with chest pain. In the present study we therefore sought
to determine the utility of S100A12 for the early diagnosis and
prognostication of STEMI among patients with chest pain.

- Question: Can circulating S100A12 serve as a useful biomarker
for the early diagnosis and prognostication of patients
with STEMI?
- Findings: Among 1,023 patients (438 of whom had STEMI),
S100A12 diagnosed STEMI more accurately than other
commonly used biomarkers of myocardial injury (troponin
and CK-MB). S100A12 was particularly useful to discriminate
the etiology of chest pain within 2 h of symptom onset, before
other biomarkers typically rise. Peak S100A12 levels were an
independent predictor of MACE within 1 year after STEMI.
- Meaning: S100A12 is a novel diagnostic biomarker which may
be used to rapidly identify patients with STEMI, especially
in the early hours after symptom onset. The peak plasma
concentration of S100A12 also provides prognostic utility
within 1 year after STEMI.

METHODS
Study Design and Participants

INTRODUCTION

The present study prospectively enrolled three patient cohorts.
The first cohort comprised 1,023 patients presenting with
acute chest pain to the emergency department of General
Hospital of Northern Theater Command, Shenyang Liaoning
Province, China, between June 2012 and November 2015.
Patients were included if they presented with acute chest pain
and/or discomfort possibly indicating AMI with symptom onset
within 24 h, were older than 18 years and were willing to
participate in the study. Exclusion criteria included patients
with known active inflammatory or autoimmune diseases, severe
heart failure, hemodynamic instability, suspected myocarditis
or pericarditis, diseases of the hematopoietic system, known
severe kidney or liver disease, known malignancy, use of
immunosuppressant agents, and previous coronary artery bypass
graft surgery. These 1023 patients served as the diagnosis cohort.
A second patient group, serving as a validation cohort, comprised
398 patients with the same inclusion and exclusion criteria
presenting to the emergency department of three different
hospitals (eAppendix 1) between May 2016 and November
2016, The third cohort comprised the subgroup of patients
with confirmed STEMI from the first cohort (n = 438) and
562 newly enrolled consecutive STEMI patients from the same
hospital between January 2016 and May 2017, in which the longterm prognostic value of S100A12 in patients with STEMI was
evaluated. This study was approved by ethics committee of all
participating centers and all patients signed informed consent.

Acute myocardial infarction (AMI) is a major worldwide cause of
morbidity and mortality (1). Early recognition and intervention
in patients with AMI, especially those with ST-segment elevation
myocardial infarction (STEMI), is crucial to salvage myocardium
and improve long-term prognosis. Currently, diagnosis of
STEMI is dependent on early elevation of cardiac biomarkers,
most commonly high-sensitivity cardiac troponin T (hscTnT)
or creatine kinase MB isoenzyme (CK-MB), in concert with
consistent symptoms and an abnormal electrocardiogram (ECG).
Optimal treatment of STEMI requires its rapid diagnosis for
emergent cardiac catheterization and primary percutaneous
coronary intervention. However, patients often present with a
non-diagnostic ECG or atypical symptoms (2). In such patients
the rapid diagnosis of STEMI (within 2–3 h of symptom onset,
the time period in which rapid reperfusion is most beneficial),
can be challenging given a delay in rise of biomarkers.
S100A12 is a member of the S100 multigene family, a
calcium binding protein which is highly associated with chronic
inflammatory disorders, including atherosclerosis and coronary
artery disease (CAD) (3, 4). Studies have demonstrated that the
expression of S100A12 is up-regulated in coronary artery plaques
of patients with sudden cardiac death (5) and carotid artery
plaques of patients with transient ischemic attack (6), suggesting
Abbreviations: AMI, acute myocardial infarction; AUC, area under the curve;
CK-MB, creatine kinase isoenzyme; hscTnT, high-sensitivity cardiac troponin
T; MACCE, major adverse cardiac and cerebral events; NSTEMI, non-STsegment elevated myocardial infarction; STEMI, ST-segment elevation myocardial
infarction; UAP, unstable angina pectoris.
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AUC) for each biomarker. Statistical analysis was performed
using SPSS version 21.0 software (IBM SPSS Inc., Chicago,
IL, USA).

and required a typical rise and fall in cardiac biomarkers
(troponins and/or CK-MB) with ECG evolution (10). STEMI
was differentiated from NSTEMI by the presence of ST-segment
elevation in at least two contiguous leads or true posterior
infarction with anterior ST-segment depression. Unstable angina
pectoris (UAP) was diagnosed in patients with normal biomarker
levels and typical angina at rest or rapid progression of previously
stable angina with a consistent ECG or positive exercise test
or cardiac catheterization showing coronary stenosis of ≥70%.
Non-coronary syndromes such as pulmonary thromboembolism
(PTE) and aortic dissection (AD) were diagnosed according to
current standards (11, 12). Patients with other diagnoses or chest
pain of unknown origin were classified as “others.”

RESULTS
Among the first cohort of 1,023 consecutive patients presenting
with acute chest pain, 438 (42.8%) were adjudicated as STEMI.
The final diagnosis in the other 585 patients were NSTEMI
(n = 248), UAP (n = 88), PTE (n = 8), AD (n = 10) and “other”
(n = 231). Baseline characteristics of STEMI versus not STEMI
patients are shown in Table 1. Mean plasma concentration of
S100A12 at the time of arrival in the emergency department
was significantly higher in patients with STEMI (520.1 ± 301.0
ng/ml) compared with other final diagnoses (NSTEMI 205.51 ±
98.15 ng/ml; UAP 181.49 ± 65.41ng/ml; AD 170.4 ± 63.5 ng/ml;
PTE 135.2 ± 45.6 ng/ml; Others 53.81 ± 26.74 ng/ml; P < 0.001
for all comparisons vs. STEMI; Figure 1A). By ROC analysis,
at an optimal cutoff value of 202.2 ng/ml, the AUC of S100A12
for the diagnosis of STEMI was 0.969 (95%CI 0.959–0.978),
which was significantly higher than the AUC for hscTnT (0.896,
95%CI 0.872–0.920) and CK-MB (0.798, 95%CI 0.767–0.829)
(both P < 0.05; Figure 1B). The sensitivity and specificity of
S100A12 for STEMI were 88.4% (95%CI 0.849–0.911) and 92.5%
(95%CI 0.889–0.941) respectively, higher than that for hscTnT
(sensitivity 84.2%, 95%CI 0.804–0.875, specificity 85.6%, 95%CI
0.811–0.890) and CK-MB (sensitivity 57.3%, 95%CI 0.525–0.619,
specificity: 91.0%, 95%CI: 0.872–0.937).
The time trend of plasma S100A12 levels in STEMI are shown
in Figure 2. Plasma S100A12 levels were markedly elevated at
30 min after hospital arrival (the approximate time of first draw),
peaked at 1–2 h and remained elevated for 12 h, followed by a
gradual decline thereafter. Elevation of plasma concentrations
of hscTnT and CK-MB in STEMI occurred later than S100A12
(hscTnT elevation began at 2 h and peaked at 12 h; CK-MB
elevation began at 4 h and peaked at 12 h).For patients presenting
with chest pain within 2 h of symptom onset (n = 150), plasma
S100A12 levels at admission were markedly elevated in patients
with a final diagnosis of STEMI (604.8 ± 441.2 ng/ml) compared
with other diagnoses (143.1 ± 102.4 ng/ml) (Figure 3A). The
AUC for S100A12 for the early (≤2 h) diagnosis of STEMI was
0.963 (95%CI 0.945–0.982), with sensitivity 82.8% (95%CI 76.2–
88.7%) and specificity 95.8% (95%CI 88.9–98.6%) compared with
an AUC of 0.860 for hscTnT (95%CI 0.812–0.908) with sensitivity
79.5% (95%CI 71.8–85.3%) and specificity 83.2% (95%CI 73.8–
89.8%) and an AUC of 0.711 for CK-MB (95%CI 0.647–0.775)
with sensitivity 62.9% (95%CI 55.0–70.9%) and specificity 74.7%
(95%CI: 64.6–82.8%) (AUC for S100A12 vs. hscTnT and vs. for
CK-MB both P < 0.05; Figure 3B).
Among the 243 patients with chest pain in the second
(validation) cohort, 150 (61.7%) were adjudicated as STEMI
and 93 (38.3%) were not STEMI. The baseline characteristics
of the second cohort were similar to those of the first cohort
(Supplementary Table S1). Plasma S100A12 levels and their
diagnostic value for STEMI were consistent to those of the first
cohort (Supplementary Table S2).

Sample Collection
Blood samples were obtained at the time of arrival at the
emergency department for all patients. Depending on the time
from symptom onset to hospital arrival, subsequent samples were
drawn at 2, 4, 6, 12, and 24 h and at 3, 7, and 30 days after
chest pain onset. Sequential sampling was terminated once the
diagnosis of STEMI was excluded.

Outcomes
All confirmed STEMI patients in the third cohort were followed
via telephone or outpatient clinic visits at 6 months and 1
year after discharge. The primary outcome was major adverse
cardiac and cerebral events (MACCE) at 1 year, a composite
of all-cause death, repeat myocardial infarction (MI), stroke, or
hospitalization for heart failure. Major secondary outcomes were
the individual components of MACCE. MI was defined according
to the Third Universal Definition of Myocardial Infarction (10).
Stroke was defined as acute focal dysfunction of the brain, retina,
or spinal cord lasting longer than 24 h, or of any duration if focal
infarction or hemorrhage was confirmed by neuro-imaging (13).
All clinical events were adjudicated by physicians blinded to the
biomarker analysis results.

Statistical Analysis
The sample size of the first and second cohorts followed guidance
for clinical studies of in-vitro diagnostic reagents from the
China Food and Drug Administration. For the third cohort,
from prior studies we assumed the MACCE rate at 1-year
after STEMI would be 7.5%. To determine a 95% confidence
interval between 6.0 and 9.0%, with two-sided alpha of 0.05
and power of 90%, and considering 10% loss of follow up, a
total of 1,000 patients would be needed, providing 60–90 events.
Categorical variables are reported as counts and percentages,
and between-group differences were assessed with chi-square
or Fisher’s exact test. Continuous variables are presented as
the mean ± SD and were compared with a two-sample ttest or one-way analysis of variance. Unless otherwise specified,
a two-sided P < 0.05 was considered to indicate statistical
significance. Time-to-event data with event rates estimated with
the Kaplan-Meier method were compared using the log-rank test.
Logistic regression analysis was used to identify the independent
predictors of MACCE. Discrimination was quantified by the
area under the receiver-operating characteristics curve (ROC
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TABLE 1 | Baseline characteristics of the cohort 1 study population.
Variable

Not STEMI
(n = 585)

STEMI
(n = 438)

P-value

Sex, male

400 (68.3)

354 (80.8)

<0.0001

Age, years

60.3 ± 10.5

59.0 ± 12.1

0.06

Body mass index, kg/m2

25.7 ± 3.3

25.6± 2.8

0.58

Heart rate, bpm

78.3 ± 12.8

79.9 ± 15.8

0.08

Blood pressure, mmHg

122.9 ± 19.5

123.5 ± 19.9

0.66

Smoking

316 (54.0)

260 (59.4)

0.09

Hypertension

339 (57.9)

252 (57.5)

0.89

Diabetes

174 (29.7)

136 (31.5)

0.65

Prior MI

92 (15.7)

35 (7.9)

0.0002

Previous stroke

98 (16.8)

82 (18.7)

0.41

Symptom onset to hospital arrival, hrs

6.4 ± 5.2

5.9 ± 5.5

0.15

TG, mmol/dl

2.0 ± 1.7

1.9 ± 1.9

0.17

HDL-C, mmol/dl

1.1 ± 0.4

1.1 ± 0.2

0.59

LDL-C, mmol/dl

2.3 ± 0.9

3.1 ± 0.8

<0.0001

GLU, mmol/dl

6.6 ± 2.2

7.7 ± 2.7

<0.0001

WBC, x 109 /L

7.8 ± 2.5

11.6 ± 3.9

<0.0001

Hs-CRP, mg/l

2.9 ± 4.6

5.4 ± 9.4

<0.0001

hscTnT, ng/ml

0.2 ± 0.5

0.9 ± 1.8

<0.0001

27.3 ± 28.9

56.0 ± 81.7

<0.0001

140.4 ± 100.7

520.1 ± 301.0

<0.0001

CK-MB, U/L
S100A12, ng/ml

Data presented are means ± SD or n (%). MI, myocardial infarction; TG, triglyceride; HDL-C, high density lipoprotein; LDL-C, low-density lipoprotein; GLU, blood glucose; WBC, white
blood cell; hs-CRP, high-sensitivity C-reactive protein; hscTnT, high-sensitivity troponin T; CK-MB, creatine kinase MB isoenzyme.

FIGURE 1 | Plasma S100A12 levels and diagnostic accuracy. Baseline plasma S100A12 concentrations at the time of hospital arrival to the emergency department
were measured by ELISA in the diagnosis cohort. (A) Bars and limit lines represent the mean ± SD. UAP, unstable angina pectoris; PTE, pulmonary thromboembolism;
AD, aortic dissection; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction. (B) Area under the curve (AUC)
for S100A12, high-sensitivity cardiac troponin T (hscTnT), creatine kinase MB isoenzyme (CK-MB) in STEMI patients. *P < 0.05 compared with all other groups.

[4.3%]), or conservatively without rapid reperfusion (n = 80
[8.0%]). During 1-year clinical follow-up, a total of 62 MACCE
events occurred in 60 patients (6.0%). The 1-year rate of MACCE
was greatest in patients in the highest peak S100A12 tertile,
intermediate in the middle tertile and least in the lowest tertile
(9.3 vs. 5.7 vs. 3.0% respectively, Ptrend = 0.0006). Higher peak
plasma S100A12 levels were also associated with an increased

Patients in the third cohort (all of whom had STEMI) were
stratified according to baseline tertile of plasma S100A12 levels
(Table 2). Diabetes, elevated hscTnT and symptom onset time
were more common in patients with high plasma S100A12
levels; other baseline characteristics were unrelated to S100A12.
The 1,000 STEMI patients were initially treated with emergent
primary PCI (n = 877 [87.7%]), fibrinolytic therapy (n = 43

Frontiers in Cardiovascular Medicine | www.frontiersin.org
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FIGURE 2 | Time trends of plasma S100A12, CK-MB and hscTnT levels in patients with STEMI. *Represents the time point when plasma concentration was first
higher than the diagnostic critical value. Chest pain time ≤30 min included 9 STEMI patients (a total of 9 samples were measured); chest pain time of 30 min to 1 h
included 28 STEMI patients (a total of 37 samples were measured); and chest pain time of 1–2 h included 113 STEMI patients (a total of 150 samples were measured).
Samples from all 150 patients were tested at each subsequent time after 2 h. Bars and limit lines represent the mean ± SEM.

FIGURE 3 | Diagnostic accuracy of S100A12 in patients presenting within 2 h of symptom onset; (A) Plasma concentration of S100A12 in patients with a final
adjudicated diagnosis of STEMI, NSTMI, UAP and others; (B) The AUC for S100A12, hscTnT, and CK-MB in the STEMI cohort presenting ≤2 h after symptom onset
(n = 150). UAP, unstable angina pectoris; PTE, pulmonary thromboembolism; AD, aortic dissection; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI,
ST-segment elevation myocardial infarction.

occurrence of which provided higher diagnostic and differential
diagnostic accuracy than hscTnT and CK-MB levels. Second,
plasma S100A12 levels were elevated at a very early stage of
STEMI (beginning at 30 min and peaking at 1–2 h), significantly
earlier than other classic myocardial biomarkers, providing
higher sensitivity and specificity for the diagnosis of STEMI
within 2 hours of symptom onset. Third, S100A12 expression
was strong in ruptured plaques and coronary artery thrombi of
patients with STEMI, co-localizing in CD68+ macrophages, and
was not elevated after myocardial necrosis from other causes.
Finally, the peak plasma S100A12 level was an independent
predictor of MACCE at 1-year in patients with STEMI, indicating
its potential clinical utility for risk stratification.
S100A12 is endogenously expressed by cells closely linked
to vascular disease including granulocytes, myeloid cells and
macrophages (14, 15). Consistent with the findings from previous
studies, the immunohistochemistry and immunofluorescence
findings from the present study in acutely aspirated coronary
thrombi and autopsy specimens from patients with STEMI

risk of all-cause death (4.2 vs. 2.4 vs. 0.9%, Ptrend = 0.03)
(Table 3). By univariable analysis advanced age, male sex, Killip
class, diabetes, history of stroke, treatment with angiotensinconverting enzyme inhibitors (ACEI) and statins at discharge,
peak S100A12 level were associated with 1-year MACCE. By
multivariable analysis, the peak plasma S100A12 level was an
independent predictor of 1-year MACCE (HR 1.001, 95%CI
1.000–1.002; P = 0.01) for all patients with STEMI (Table 4) and
those treated with primary PCI (HR 1.001, 95%CI 1.000–1.002,
P = 0.01; Supplementary Table S3). Peak levels of hscTnT and
CK-MB were not significantly associated with 1-year MACCE.

DISCUSSION
The present study is the first investigation to our knowledge
to evaluate the diagnostic accuracy and prognostic utility of
plasma S100A12 levels in patients with chest pain and confirmed
STEMI. The major findings are as follows: First, a high plasma
level of S100A12 was identified in patients with STEMI, the
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TABLE 2 | Baseline characteristics of cohort 3 STEMI patients stratified by baseline S100A12 tertiles.
Variable

Overall
(n = 1,000)

Plasma S100A12 levels on admission
Lowest tertile
(n = 333)

Median tertile
(n = 332)

Highest tertile
(n = 335)

P-value

0.72

Sex, male

811 (81.1)

272 (81.7)

272 (81.9)

267 (79.7)

Age, years

59.4 ± 12.1

60 ± 12.6

59 ± 11.2

59.3 ± 12.5

0.59

Hypertension

597 (59.7)

198 (59.5)

209 (62.9)

190 (56.7)

0.26

Current smoking

572 (57.2)

187 (56.2)

180 (54.2)

205 (61.2)

0.17

Diabetes

336 (33.6)

96 (28.8)

107 (32.2)

133 (39.7)

0.01

Prior MI

89 (8.9)

30 (9.0)

22 (6.7)

37 (11.0)

0.13

Previous stroke

186 (18.6)

62 (18.6)

59 (17.8)

65 (19.4)

0.86

Symptom onset to hospital arrival, hrs

6.5 ± 5.0

8.2 ± 6.3

6.1 ± 4.2

5.4 ± 3.8

<0.0001

Killip class ≥2

200 (2.0)

57 (17.1)

72 (21.7)

71 (21.2)

0.27

Primary PCI

877 (87.7)

292 (87.7)

293 (88.3)

292 (87.2)

0.91

Thrombolysis

43 (4.3)

15 (4.5)

15 (4.5)

13 (3.8)

0.89

No reperfusion

80 (8.0)

24 (7.2)

25 (7.5)

31 (9.3)

0.58

Radial access

834 (83.4)

275 (82.6)

276 (83.1)

283 (84.5)

0.78

Femoral access

134 (13.4)

48 (14.4)

44 (13.3)

42 (12.5)

0.78

LAD

650 (67.1)

214 (66.3)

223 (69.7)

213 (65.5)

0.49

LCX

279 (28.8)

97 (30.0)

89 (27.8)

93 (28.6)

0.82

RCA

457 (47.2)

160 (49.5)

142 (44.4)

155 (47.7)

0.41
0.31

Infarct artery

LM
Use of Bivalirudin
LVEF, % (mean ± SD)

17 (1.8)

3 (0.9)

8 (2.5)

6 (1.8)

286 (29.5)

82 (25.4)

95 (29.7)

109 (33.5)

0.08

56 ± 8

56 ± 9

55 ± 9

55 ± 8

0.43

Aspirin

991 (99.1)

330 (99.4)

329 (99.1)

332 (99.1)

1.00

Clopidogrel/Ticagrelor

993 (99.3)

330 (99.4)

331 (99.7)

331 (98.8)

0.61

β-Blockers

814 (81.4)

273 (81.9)

267 (80.4)

274 (81.8)

0.85

ACE inhibitors

742 (74.2)

242 (72.6)

253 (76.2)

247 (73.7)

0.57

Statins

966 (96.6)

320 (96.1)

322 (96.9)

324 (96.7)

0.81

TG, mmol/dl

1.8 ± 1.8

1.7 ± 1.9

1.9 ± 1.9

1.8 ± 1.7

0.69

LDL-C, mmol/dl

3.1 ± 0.8

3.0 ± 0.8

3.1 ± 0.8

3.1 ± 0.9

0.37

HDL-C, mmol/dl

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.2

1.1 ± 0.2

0.28

GLU, mmol/dl

8.1 ± 3.0

7.9 ± 3.0

8.1 ± 2.8

8.2 ± 3.3

0.43

WBC, 109 /L

11.5 ± 3.9

11.4 ± 3.8

11.4 ± 3.9

11.8 ± 4.0

0.26

hscTnT, ng/ml

0.9 ± 1.8

0.60 ± 1.5

0.9 ± 2.0

0.9 ± 1.9

0.01

Hs-CRP, mg/l

5.7 ± 9.1

5.7 ± 9.3

5.8 ± 9.4

5.5 ± 8.4

0.91

CK-MB, U/L

56.8 ± 79.9

54.8 ± 84.6

57.9 ± 77.2

57.6 ± 78.2

0.87

517.7 ± 306.7

206.9 ± 72.7

498.9 ± 116.4

845.3 ± 233.7

<0.0001

S100A12, ng/ml

Data are mean ± SD or n (%). PCI, percutaneous coronary intervention; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery; LM, left main; LVEF, left
ventricular ejection fraction; ACE, angiotensin-converting enzyme; MI, myocardial infarction; TG, triglyceride; HDL-C, high density lipoprotein; LDL-C, low-density lipoprotein; GLU, blood
glucose; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein; hscTnT, high-sensitivity troponin T; CK-MB, creatine kinase MB isoenzyme.

TABLE 3 | One-year clinical outcomes in cohort 3 STEMI patients according to peak S100A12 tertiles.
Endpoint

Lowest tertile
(n = 333)

Middle tertile
(n = 332)

Highest tertile
(n = 335)

Trend P-value

MACCE*

10 (3.0%)

19 (5.7%)

31 (9.3%)

0.0006

- All-cause death*

5 (0.9%)

8 (2.4%)

14 (4.2%)

0.03

- Reinfarction

1 (0.3%)

4 (1.2%)

5 (1.8%)

0.12

- Stroke

2 (0.6%)

2 (0.6%)

6 (1.8%)

0.12

- Heart failure hospitalization

2 (0.6%)

6 (1.8%)

7 (2.1%)

0.12

MACCE, major adverse cardiac and cerebral events. *P < 0.05 between three groups.
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myonecrosis. Plasma S100A12 was elevated as soon as 30 min
after STEMI onset and peaked at 1–2 h, providing very good
sensitivity and excellent specificity for the differential diagnosis
of symptoms within 2 h, substantially better than for hscTnT
and CK-MB. The earlier and more accurate discrimination
of STEMI provided by S100A12 may afford faster triage
and initiation of reperfusion therapy, potentially improving
clinical outcomes.
In addition to its value in the early diagnosis of STEMI, the
peak level of S100A12 was an independent predictor of the 1year prognosis after STEMI, in particular all-cause mortality.
Although the precise mechanisms are unknown, several possible
reasons might explain the association between S100A12 and
clinical outcomes. First, inflammation plays a central role in
the development and progression of atherosclerosis. Previous
studies have demonstrated that hs-CRP, a classic biomarker of
systemic inflammation, is useful in predicting adverse clinical
outcomes in various cardiovascular disease settings (20, 21).
Like hs-CRP, S100A12 is a sensitive concentration-dependent
biomarker which correlates with the extent of inflammation
and outcomes, as demonstrated in the present and previous
studies (22, 23). Notably, in the present study the level of
S100A12 was a stronger predictor of prognosis than was hs-CRP.
Second, as S100A12 is derived from ruptured coronary plaques
and is highly expressed in coronary thrombi, its concentration
may reflect the severity of the underlying atherosclerotic plaque
(ruptured and stable), as an indicator of the vulnerability
of the patient. Notably, the peak levels of hscTnT and CKMB were not associated with MACCE at 1-year in the
present study.
Our study has limitations. First, although the principal
findings from the diagnosis cohort were validated in a second
dataset from 3 independent hospitals, additional confirmatory
studies should be performed in an even larger population and
in different geographies. Second, plasma S100A12 concentrations
currently must be measured by ELISA, and commercial
clinical laboratory analyzers such as those widely used for
hscTnT and CK-MB are unavailable. Third, S100A12 is not
specific to cardiac disease. Other diseases such as stroke
and immunologic and infectious diseases are also associated
with elevation of plasma S100A12 levels. Thus, the diagnostic
accuracy of S100A12 to diagnose STEMI will depend on the
clinical characteristics and presentation of the test population;
like hscTnT, its specificity will likely decline if applied
to non-cardiac and miscellaneous conditions. Finally, we
cannot rule out the role of unmeasured confounders in our
multivariable model.
In conclusion, in the present large-scale study, plasma
levels of S100A12 were elevated in the early stage of
STEMI, had stronger discrimination for the diagnosis of
STEMI than CK-MB or hscTnT, and were an independent
predictor of 1-year MACCE, including all-cause mortality.
Compared to classic biomarkers of myocardial necrosis,
S100A12 may offer several advantages for the early
evaluation of patients with chest pain to guide rapid
reperfusion therapy and provide prognostic utility in patients
with STEMI.

TABLE 4 | Independent predictors of 1-year MACCE in cohort 3 patients with
STEMI.
Variable

Multiple regression
HR (95% CI)

P-value

Age, years

1.009 (0.986-1.034)

0.45

Sex, male

0.661 (0.366–1.193)

0.17

Diabetes

1.748 (1.028–2.971)

0.04

Previous stroke

1.772 (1.007–3.120)

0.047

Killip class ≥2

2.214 (1.273–3.851)

0.005

Primary PCI

0.728 (0.368–1.443)

0.36

ACE inhibitor use at discharge

0.513 (0.298–0.882)

0.02

Statin use at discharge

0.282 (0.108–0.737)

0.01

Symptom onset to hospital arrival, hrs

1.019 (0.968–1.073)

0.47

Peak hsTnT, ng/ml

1.009 (0.923–1.023)

0.84

Peak CK–MB, U/L

1.001 (0.999–1.002)

0.39

Peak S100A12, ng/ml

1.001 (1.000–1.002)

0.01

PCI, percutaneous coronary intervention; LAD, left anterior descending; LCX, left
circumflex artery; RCA, right coronary artery; LM, left main; LVEF, left ventricular ejection
fraction; ACE, angiotensin-converting enzyme; MI, myocardial infarction; TG, triglyceride;
HDL-C, high density lipoprotein; LDL-C, low-density lipoprotein; GLU, blood glucose;
WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein; hscTnT, high-sensitivity
troponin T; CK-MB, creatine kinase MB isoenzyme.

suggests that the increase in plasma S100A12 in STEMI derives
from its acute release from CD68+ macrophages in ruptured
plaques, a mechanism quite different than the elevation of
biomarkers derived from myocardial necrosis such as CK-MB
and hscTnT (16). Plasma S100A12 was slightly increased in
patients with non-plaque related chest pain, such as PTE and
AD, possibly due to systemic or focal inflammation. However,
extremely high levels of S100A12 were only seen with STEMI.
We also observed that plasma S100A12 levels were low in
patients with stable CAD, slightly increased in UAP and modestly
increased in NSTEMI. This suggests that plasma S100A12 levels
might reflect plaque burden, composition, focal inflammation,
and instability of thrombotic atherosclerotic lesions. In this
regard optical coherence tomography studies have reported
that plaque ruptures occurred in 71% of patients presenting
with sudden death after STEMI vs. 43% after NSTEMI (17). It
has further been described that plaques in STEMI are usually
more severe, larger and have greater lipid and macrophage
content compared with those in NSTEMI. These distinctions
may underlie the differences in plasma S100A12 levels between
STEMI and NSTEMI.
A notable implication from the present study regards the
potential utility of S100A12 for the early diagnosis of STEMI.
Elevation of classic myocardial biomarkers such as hscTnT
and CK-MB do not occur for 2–4 h after onset of STEMI as
seen in the present and previous studies (18, 19). This delay
may lead to uncertainty in the rapid diagnosis of STEMI,
especially in patients presenting early with atypical symptoms
and/or ECGs. In patients with STEMI the elevation of S100A12
due to coronary artery plaque rupture and thrombi formation
precedes the rise in hscTnT and CK-MB due to subsequent
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